Periodic assessment of serum neurofilament-light chain (sNfL) may be useful to identify subclinical disease activity, according to an analysis from the APLIOS study (Bar-Or et al. Neurol Ther 2023;12:303-317). Read More
Latest News
Is vitamin D supplementation justified?
April 5, 2023Vitamin D supplementation is routinely recommended for patients with multiple sclerosis. However, numerous studies have reported that there is no benefit on clinical or MRI outcomes associated with high-dose vitamin D. Read More
CLINICAL CASES IN MS – A YOUNG WOMAN WITH BREAKTHROUGH DISEASE ON FINGOLIMOD
March 29, 2023Click here to watch Dr. Virender Bhan discuss the case and the responses to the survey.
Amanda, 31, a computer programmer was diagnosed with RRMS in 2014. She was initially treated with glatiramer acetate, but experienced ongoing disease activity. She was switched to fingolimod in 2016 and was clinically and radiologically stable for three years. Read More
Putting biomarkers into practice
March 8, 2023ACTRIMS Forum 2023
Neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) have the potential to be useful biomarkers of axonal damage and neurodegeneration. However, additional research is needed to determine normative values and to track the significance of biomarker changes over time. A number of groups addressed these issues at the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2023, held February 23-25, 2023 in San Diego CA. Read More